Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Myelinating glia differentiation is regulated by extracellular matrix elasticity.
Poster 378 Transverse Myelitis Secondary to Infectious Mononucleosis: A Case Report.
Pathophysiology, assessment and management of multiple sclerosis fatigue: an update.
Natalizumab treatment leads to an increase in circulating CXCR3-expressing B cells.
[Multiple sclerosis vaccine: possibilities of the use of dendritic cells immunomodulatory potential].
Imaging of progressive weakness or numbness of central or peripheral origin.
Imaging of noninfectious inflammatory disorders of the spinal cord.
Rationale, design, and methods of a non-interventional study to establish safety, effectiveness, quality of life, cognition, health-related and work capacity data on Alemtuzumab in multiple sclerosis patients in Germany (TREAT-MS).
Safety and efficacy of amiselimod in relapsing multiple sclerosis (MOMENTUM): a randomised, double-blind, placebo-controlled phase 2 trial.
MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study.
The effects of progressive muscular relaxation as a nursing procedure used for those who suffer from stress due to multiple sclerosis.
Biochemical, cell biological, pathological, and therapeutic aspects of Krabbe's disease.
Rethinking the importance of paroxysmal and unusual symptoms as first clinical manifestation of multiple sclerosis: They do matter.
Delayed iron deposit and atrophy of the putamen in a case with osmotic demyelination syndrome.
Interleukin-13 immune gene therapy prevents CNS inflammation and demyelination via alternative activation of microglia and macrophages.
Multiple sclerosis is accompanied by lack of KIR2DS1 gene: A meta-analysis.
A Proteogenomic Approach to Understanding MYC Function in Metastatic Medulloblastoma Tumors.
γδ T Cells and NK Cells - Distinct Pathogenic Roles as Innate-Like Immune Cells in CNS Autoimmunity.
Nonnative SOD1 trimer is toxic to motor neurons in a model of amyotrophic lateral sclerosis.
The efficacy of a Mindfulness Based Intervention for depressive symptoms in patients with Multiple Sclerosis and their caregivers: study protocol for a randomized controlled clinical trial.
Central pontine myelinolysis in a case of alcohol dependence syndrome.
MicroRNAs associated with the pathogenesis of multiple sclerosis.
From Natural Product to the First Oral Treatment for Multiple Sclerosis: The Discovery of FTY720 (Gilenya™)?
Programmed cell death and natural killer cells in multiple sclerosis: new potential therapeutic targets?
Identification of galectin-3 as a possible antibody target for secondary progressive multiple sclerosis.

Pages